Compass Therapeutics raises $80M in PIPE led by Enavate; extends cash runway to 2026

Compass Therapeutics, Inc.

Issues 25M shares at $3.21 each for gross proceeds of ~$80M; closing expected by Nov 8, 2022.
PIPE led by Enavate Sciences with participation from Janus Henderson, Vivo Capital, OrbiMed, and others.
New director James P. Boylan (CEO of Enavate) appointed to board, effective upon closing.
Proceeds to fund CTX-009, CTX-471, CTX-8371 clinical programs and preclinical work; cash runway extended into 2026.

item 1.01 item 5.02 item 3.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James P. Boylan

Director

CMPX · Compass Therapeutics, Inc.

Filed: November 2, 2022, 7:59 PM ET

On November 1, 2022, the Board appointed Mr. Boylan to join as a director of the Board, effective upon the closing of the Private Placement.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

James P. Boylan was appointed as Director at Compass Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 1, 2022, the Board appointed Mr. Boylan to join as a director of the Board, effective upon the closing of the Private Placement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

Compass Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $80 million (effective 2022-11-02).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $80 million
Effective: 2022-11-02

Exact text from the filing

On November 2, 2022, Compass Therapeutics, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 25,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $3.21 per share.

View on SEC.gov

Browse all material agreements →

Compass Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.